{
    "clinical_study": {
        "@rank": "4835", 
        "arm_group": [
            {
                "arm_group_label": "Pelubiprofen IR (Pelubiprofen 30 mg)", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Pelubiprofen SR (Pelubiprofen 45 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Pelubiprofen SR (Pelubiprofen 45 mg) fed condition", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "Part 1 : A randomized, open Label, multiple doses, cross-over, phase I trial to investigate\n      the pharmacokinetics of Pelubiprofen IR (Pelubiprofen 30mg) TID and Pelubiprofen SR\n      (Pelubiprofen 45 mg) BID in healthy male volunteers Part 2 : A randomized, open label,\n      single dose, cross-over, Phase I trial to investigate the food effect of Pelubiprofen SR\n      (Pelubiprofen 45 mg) in healthy male volunteers"
        }, 
        "brief_title": "Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects", 
        "condition": "Healthy Males", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult healthy males aged 20~40 years\n\n          -  BMI valued over 19 kg/m2, below 27 kg/m2\n\n          -  Subjects whose blood pressure ; systolic BP over 90mmHg below 140mmHg, diastolic BP\n             over 60mmHg below 90mmHg, stable station pulse over 45 bpm below 100 bpm\n\n          -  Subjects who agree with double protective contraception or able to certificate\n             already sterilization operation 1 day before administration of Investigational new\n             drugs within 14 days after completion\n\n          -  Subjects who voluntarily agreed with written consent\n\n        Exclusion Criteria:\n\n          -  Subjects with clinically significant disease or past medical history in hepatic,\n             renal, GI tract, respiratory, musculoskeletal, endocrine, neuropsychiatry, blood\n             tumor and cardiovascular system\n\n          -  Subjects with GI tract disease (eg. Crohn's disease, peptic ulcer etc.) or surgery\n             (except appendectomy and herniotomy) influence on administration Investigational new\n             drugs\n\n          -  Subjects with hypersensitivity reaction or clinically significant disease in drugs\n             (Aspirin, NSAID anti-inflammatory agents and antibiotics) including Pelubiprofen and\n             Food"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870102", 
            "org_study_id": "DW330SR-1002(Ver1.1.)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pelubiprofen IR (Pelubiprofen 30 mg)", 
                "intervention_name": "Pelubiprofen IR (Pelubiprofen 30mg) TID", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Pelubiprofen SR (Pelubiprofen 45 mg)", 
                    "Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition", 
                    "Pelubiprofen SR (Pelubiprofen 45 mg) fed condition"
                ], 
                "intervention_name": "Pelubiprofen SR (Pelubiprofen 45 mg) BID", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Open Label, Cross-over, Phase 1 Trial to Investigate the Pharmacokinetics in Multi-dose and the Food Effect in Single-dose of Pelubiprofen IR and Pelubiprofen SR in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "(Part1) Cmax,ss of Pelubiprofen IR (Pelubiprofen 30mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.25h, 0.5.h, 0.75h, 1h, 1.5h, 2h, 4h, 6h, 6.5h, 7h, 8h, 12h, 12.5h, 13h, 14h, 24h, 60h, 72h, 72.25h, 72.5h, 72.75h, 73h, 73.5h, 74h, 76h, 78h, 80h, 84h, 96h (total 30 times)"
            }, 
            {
                "measure": "(Part1) Cmax,ss of Pelubiprofen SR (Pelubiprofen 45 mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 13h, 14h, 16h, 24h, 60h, 72h, 72.5h, 73h, 73.5h, 74h, 74,5h. 75h. 75.5h, 76h, 77h, 78h, 80h, 84h, 96h (total 32 times)"
            }, 
            {
                "measure": "(Part1) Dose normalized AUC\u03c4,ss of Pelubiprofen IR (Pelubiprofen 30mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.25h, 0.5.h, 0.75h, 1h, 1.5h, 2h, 4h, 6h, 6.5h, 7h, 8h, 12h, 12.5h, 13h, 14h, 24h, 60h, 72h, 72.25h, 72.5h, 72.75h, 73h, 73.5h, 74h, 76h, 78h, 80h, 84h, 96h (total 30 times)"
            }, 
            {
                "measure": "(Part1) Dose normalized AUC\u03c4,ss of Pelubiprofen SR (Pelubiprofen 45 mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 13h, 14h, 16h, 24h, 60h, 72h, 72.5h, 73h, 73.5h, 74h, 74,5h. 75h. 75.5h, 76h, 77h, 78h, 80h, 84h, 96h (total 32 times)"
            }, 
            {
                "measure": "(Part2) Cmax of Pelubiprofen IR (Pelubiprofen 30mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)"
            }, 
            {
                "measure": "(Part2) Cmax of Pelubiprofen SR (Pelubiprofen 45 mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)"
            }, 
            {
                "measure": "(Part2) AUClast of Pelubiprofen IR (Pelubiprofen 30mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)"
            }, 
            {
                "measure": "(Part2) AUClast of Pelubiprofen SR (Pelubiprofen 45 mg)", 
                "safety_issue": "No", 
                "time_frame": "0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}